A new study, led by researchers at the University of Liverpool, has revealed how pathogenic bacteria construct tiny ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...